1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Massachusetts >
  6. Turn.bio Acquires ARMMs Delivery Technology

Divestiture • Life Science

Turn.bio Acquires ARMMs Delivery Technology

On March 26, 2025, Turn.bio acquired life science company ARMMs Delivery Technology from Vesigen Therapeutics

Acquisition Context
  • This is Turn.bio’s 1st transaction in the Life Science sector.
  • This is Turn.bio’s 1st transaction in the United States.
  • This is Turn.bio’s 1st transaction in Massachusetts.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary
Date March 26, 2025
Target ARMMs Delivery Technology
Sector Life Science
Buyer(s) Turn.bio
Sellers(s) Vesigen Therapeutics
Deal Type Divestiture

Target Company

ARMMs Delivery Technology

Cambridge, Massachusetts, United States
ARMMs Delivery Technology uses a unique class of human extracellular vesicles to deliver therapeutic payloads, such as RNA, proteins, and gene-editing complexes, directly into the cytoplasm of target cells. ARMMs Delivery Technology is based in Cambridge, Massachusetts
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Turn.bio

San Francisco, California, United States
Category Company
Sector Life Science
DESCRIPTION

Turn.bio focuses on developing mRNA medicines that enable the body to heal itself by reprogramming specific cells to fight disease or repair damaged tissue. Turn.bio is based in San Francisco, California.

Deal Context for Buyer #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
State: Massachusetts 1 of 1
Country: United States 1 of 1
Year: 2025 1 of 1

Seller Profile 1

SELLER

Vesigen Therapeutics

Cambridge, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Vesigen Therapeutics specializes in developing intracellular therapeutic products using its patented ARRDC1-mediated microvesicles (ARMMs) technology. Vesigen Therapeutics is based in Cambridge, Massachusetts.

Deal Context for Seller #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
State: Massachusetts 1 of 1
Country: United States 1 of 1
Year: 2025 1 of 1

Explore Related M&A Activity

Life Science M&A - Divestiture M&A Deals - Massachusetts M&A - United States M&A - 2025 M&A

Mergr

Solution for

Product

Company

Legal